Supplementary Table 1. Demographic and clinical characteristics of the study cohort.

Characteristic	ALL n=88	Normal n=20 (22.73%)	Endo n=33 (37.50%)	SOC n=21 (23.86%)	EAOC[a] n=14 (15.91%)	p-value[b]
Age at presentation (year), mean(SD)	46.84(17.41)	38.75(14.11)	36.24(10.20)	65.52(12.46)	55.36(14.61)	**<0.0001**
Gravidity, median (IQR)[b]	1(0,3)	NA[d]	0(0,1)	2.5(1,3)	0.5(0,2)	**0.0092**
Parity, median (IQR)[c]	1(0,2)	NA	0(0,1)	2.5(1,3)	0.5(0,2)	**0.0071**
Body mass index (kg/m2), mean(SD)	26.27(5.36)	NA	26.27(5.09)	24.94(5.43)	27.92(5.85)	0.4417
Race (White), n (%)	73(83.91)	9(45.00)	30(90.91)	20(100.00)	14(100.00)	**<0.0001**
History of tobacco use, n (%)	19(29.23)	NA	9(29.03)	7(35.00)	3(21.43)	0.7240
History of alcohol use, n (%)	31(48.44)	NA	17(54.84)	7(35.00)	7(53.85)	0.6835
History of endometriosis, n (%)	19(65.22)	NA	17(68.00)	0(0)	2(66.67)	0.7186
History of oral contraceptive pill use, n (%)	26(81.25)	NA	21(84.00)	2(66.67)	3(75.00)	0.5445
Postmenopausal, n (%)	21(34.43)	NA	2(6.45)	12(70.59)	7(53.85)	**0.0002**
Family history of cancer, n (%)	28(45.16)	NA	11(37.93)	11(55.00)	6(46.15)	0.4710
Stage of disease, n (%)		NA	NA			
Early	11(31.43)			3(14.29)	8(57.14)	**0.0084**
Late stage	24(68.57)			18(85.71)	6(42.86)	

[a] EAOC group comprises n=6 endometrioid (50%), n=7 clear cell tumors (48.2%) and n=1 (7.1%) mixed histology of clear cell/endometrioid type
[b] ANOVA or Kruskal-Wallis test for continuous variables; Chi-square test or Cochran-Mantel-Haenszel Chi-square test for categorical variables
[c] IQR, Interquartile Range (25th percentile, 75th percentile)
[d] NA, not available

Supplementary Table 2. List of the 24 miRNAs identified by genome-wide plasma miRNA expression profiling from healthy controls (n=6), endometriosis patients (n=7), and EAOC patients (n=7).

hsa-miR-1978	hsa-miR-1974	hsa-miR-1977	hsa-miR-16	hsa-miR-1973	hsa-miR-195	hsa-miR-191	hsa-miR-652
hsa-miR-1308	hsa-miR-1975	hsa-miR-15b	hsa-miR-1979	hsa-miR-21	hsa-miR-766	hsa-miR-628-3p	hsa-miR-4313
hsa-miR-1246	hsa-miR-376a	hsa-miR-744	hsa-miR-1274a	hsa-miR-1915	hsa-miR-362-5p	hsa-miR-4284	hsa-miR-132

Supplementary Table 3. The 10 most differentially expressed miRNAs in pair-wise comparisons between SOC patients and healthy controls, endometriosis, or EAOC samples.

SOC (n =21) vs Healthy (n = 20)	W.pvalue	a.W.pvalue	FC
hsa-miR-4284	0.00028	0.00504	6.96
hsa-miR-1974	0.00086	0.00774	8.56
hsa-miR-16	0.00243	0.01458	4.56
hsa-miR-1977	0.00393	0.01769	2.49
hsa-miR-1975	0.00728	0.02621	0.39
hsa-miR-195	0.02323	0.06037	2.64
hsa-miR-1978	0.02521	0.06037	2.59
hsa-miR-21	0.02683	0.06037	2.08
hsa-miR-362-5p	0.03142	0.06284	1.76
hsa-miR-15b	0.04500	0.07747	2.31

SOC (n =21) vs Endo (n = 33)	W.pvalue	a.W.pvalue	FC
hsa-miR-15b	0.00923	0.08226	0.23
hsa-miR-191	0.01005	0.08226	0.27
hsa-miR-1973	0.01743	0.08226	0.48
hsa-miR-362-5p	0.01828	0.08226	0.52
hsa-miR-16	0.06761	0.22134	0.25
hsa-miR-21	0.07378	0.22134	0.25
hsa-miR-195	0.10272	0.26414	0.31
hsa-miR-1308	0.23086	0.51146	0.49
hsa-miR-1974	0.25573	0.51146	0.59
hsa-miR-652	0.30405	0.54729	0.56

SOC (n = 21) vs EAOC (n = 14)	W.pvalue	a.W.pvalue	FC
hsa-miR-21	0.00006	0.00102	0.06
hsa-miR-16	0.00014	0.0011	0.05
hsa-miR-191	0.00021	0.0011	0.12
hsa-miR-15b	0.00026	0.0011	0.13
hsa-miR-1975	0.00126	0.00428	0.23
hsa-miR-1246	0.00259	0.00734	0.33
hsa-miR-362-5p	0.00399	0.0088	3.71
hsa-miR-1979	0.00414	0.0088	0.23
hsa-miR-1973	0.01101	0.02011	0.29
hsa-miR-195	0.01183	0.02011	0.24